How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And DMD Uncertainty [Yahoo! Finance]
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: Yahoo! Finance
Analysts recently trimmed their fair value estimate for PTC Therapeutics from US$87.93 to US$86.50, a modest 1.6% cut that captures a slightly more cautious stance. This shift sits alongside a wide mix of analyst ratings, with fresh price targets clustered between US$82 and US$120 as views on Sephience, the DMD franchise and execution risk continue to evolve. As you read on, you will see how these moving pieces fit together and what to watch as the narrative around PTC Therapeutics develops. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value PTC Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways RBC Capital, BofA, Morgan Stanley and Barclays all maintain positive stances, pointing to Sephience as a key contributor in their models and a factor that, in RBC's view, helps offset pressure on the DMD franchise. Morgan Stanley and Barclays lifted their price targets to US$92 and US$120, respectivel
Show less
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- PTC Therapeutics (PTCT) had its "hold" rating reaffirmed by Jefferies Financial Group Inc.. They now have a $76.00 price target on the stock, down from $91.00.MarketBeat
- PTC Therapeutics (PTCT) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of DirectorsPR Newswire
- Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth And Sephience Execution Shape Expectations [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
PTCT
Earnings
- 2/19/26 - Miss
PTCT
Sec Filings
- 4/6/26 - Form 4
- 4/6/26 - Form 144
- 4/3/26 - Form 4
- PTCT's page on the SEC website